Oral Antivirals for Chronic Hepatitis B

Albert D. Min, Jules L. Dienstag

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Four oral antiviral agents have been approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B: lamivudine, adefovir, entecavir, and telbivudine. This article reviews the durability of response, dose regimen, predictors of response, safety, and problems with resistance of these four agents and of promising agents currently in phase III clinical trials for the treatment of patients who have hepatitis B e antigen-positive and -negative chronic hepatitis B.

Original languageEnglish
Pages (from-to)851-868
Number of pages18
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 2007
Externally publishedYes


Dive into the research topics of 'Oral Antivirals for Chronic Hepatitis B'. Together they form a unique fingerprint.

Cite this